KLOW vs GLOW Peptide: The Evidence on Each Ingredient
KLOW vs GLOW peptide: KLOW and GLOW are seller names for peptide blends, and no FDA label or published study defines what either contains. The strongest named record on their ingredients is the FDA's April 2026 compounding safety page, which says it has found no human exposure data for TB-500 or for KPV. A 2025 review of BPC-157 found 35 lab and animal studies and 1 clinical study. GHK-Cu has small human trials, mostly of face creams, says a 2026 systematic review. We found no trial of either blend.
Sources: FDA safety page: US FDA web page, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (page dated 22 April 2026, retrieved October 2026). Supports: the GHK-Cu, BPC-157, TB-500 (thymosin beta-4 fragment, LKKTETQ) and KPV entries: immune reaction risk and missing human exposure data; Systematic review: Vasireddi N et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS Journal, November 2025. PMID 40756949. Supports: 36 studies (35 preclinical, 1 clinical); no clinical safety data; no FDA approval; banned in professional sports; Systematic review: Najafi N et al. A systematic review of the mechanisms and therapeutic applications of GHK-Cu in topical microneedle delivery. Archives of Internal Medicine Research, July 2026. PMID 42787770. Supports: human trials are small and mostly facial creams
Short answer
- KLOW vs GLOW: which is different, and how?
- No record can say. KLOW and GLOW are seller names for blends, and no FDA label or published study defines what either contains or compares them. The mix can vary by seller, so the only comparison is the ingredient list on each product.
- Has either blend been tested?
- No. We searched PubMed, Europe PMC and ClinicalTrials.gov. We found no study of a KLOW or GLOW blend, or of these peptides given together.
- What is the evidence for each ingredient?
- GHK-Cu: small human trials, mostly face creams (2026 systematic review). BPC-157: 35 lab and animal studies and 1 clinical study (2025 systematic review). TB-500: no human exposure data (FDA). KPV: mouse studies only, and no human exposure data (FDA).
Sources: Systematic review: Najafi N et al. A systematic review of the mechanisms and therapeutic applications of GHK-Cu in topical microneedle delivery. Archives of Internal Medicine Research, July 2026. PMID 42787770. Supports: human trials are small and mostly facial creams; Systematic review: Vasireddi N et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS Journal, November 2025. PMID 40756949. Supports: 36 studies (35 preclinical, 1 clinical); no clinical safety data; no FDA approval; banned in professional sports; Animal study (mice): Kannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases, March 2008. PMID 18092346. Supports: anti-inflammatory effects in 2 mouse colitis models; FDA safety page: US FDA web page, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (page dated 22 April 2026, retrieved October 2026). Supports: the GHK-Cu, BPC-157, TB-500 (thymosin beta-4 fragment, LKKTETQ) and KPV entries: immune reaction risk and missing human exposure data
What Do the Names KLOW and GLOW Mean?
KLOW and GLOW are product names used by sellers, not names of medicines, and no FDA label, drug database or published study defines either one. We searched PubMed, Europe PMC and ClinicalTrials.gov and found no study of either blend.
That matters for anyone comparing them. A blend name tells you little on its own. Two products with the same name can list different peptides, or different amounts.
This page does not guess at a recipe. Instead it covers four peptides that come up when people discuss these names: GHK-Cu, BPC-157, TB-500 and KPV. If a product label lists any of them, the evidence for that peptide is below. Our KLOW protocol page looks at the same four peptides from a different angle.
KLOW vs GLOW: What Is the Difference?
The difference between KLOW and GLOW cannot be confirmed, because no label or study defines either blend and no study compares them. The only fair way to compare is one ingredient at a time. Use whatever the product label lists.
If the two labels differ by KPV, the gap is easy to describe. KPV has mouse data and no human data. A 2008 study found it cut inflammation in 2 mouse models of colitis. Colitis is a type of bowel inflammation. The FDA says it has found no human exposure data on products with KPV by any route.
No study has compared KLOW with GLOW. No study has tested what happens when these peptides are given together. So any claim that one blend works better or faster has no trial behind it.
Sources: Animal study (mice): Kannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases, March 2008. PMID 18092346. Supports: anti-inflammatory effects in 2 mouse colitis models; FDA safety page: US FDA web page, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (page dated 22 April 2026, retrieved October 2026). Supports: the GHK-Cu, BPC-157, TB-500 (thymosin beta-4 fragment, LKKTETQ) and KPV entries: immune reaction risk and missing human exposure data
Evidence by Ingredient
GHK-Cu has small human cream trials, BPC-157 has 1 clinical study in a 2025 systematic review, and the FDA found no human exposure data for TB-500 or KPV. This table shows the strongest evidence we found for each, and what the FDA says about compounded forms.
| Peptide | What it is | Best evidence found | FDA note |
|---|---|---|---|
| GHK-Cu | The human tripeptide GHK bound to copper | Small human trials, mostly facial creams. A 2025 review notes a surprising absence of clinical studies in anti-wrinkle products. | Shots may cause immune reactions; little human safety data |
| BPC-157 | A lab-made peptide of 15 amino acids (a pentadecapeptide) | A 2025 review found 36 studies: 35 preclinical and 1 clinical. A phase 2 placebo trial is registered. | May cause immune reactions for some routes; purity and testing concerns |
| TB-500 | A fragment of thymosin beta-4 (LKKTETQ) | The FDA found no human exposure data. A human trial exists only for recombinant thymosin beta 4, a different product. | No human data found |
| KPV | A three amino acid peptide taken from a melanocortin hormone | Mouse studies: less gut inflammation in 2 mouse colitis models | No human data by any route; safety facts lacking |
A wider view comes from a 2026 scoping review of six peptides used in sport: BPC-157, TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu. It found that 67% of the papers used animal models (PMID 42578445). It concluded that claimed benefits for recovery and performance remain unsubstantiated by current human trials.
Sources: Review: Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition, 2008. PMID 18644225. Supports: what GHK-Cu is; controlled studies on aged skin (wrinkles, firmness); Review: Mortazavi SM et al. Topically applied GHK as an anti-wrinkle peptide: advantages, problems and prospective. BioImpacts, 2025. PMID 39963574. Supports: the absence of clinical studies of GHK-Cu in anti-wrinkle products; Systematic review: Najafi N et al. A systematic review of the mechanisms and therapeutic applications of GHK-Cu in topical microneedle delivery. Archives of Internal Medicine Research, July 2026. PMID 42787770. Supports: human trials are small and mostly facial creams; Systematic review: Vasireddi N et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS Journal, November 2025. PMID 40756949. Supports: 36 studies (35 preclinical, 1 clinical); no clinical safety data; no FDA approval; banned in professional sports; Trial registry record: ClinicalTrials.gov record NCT07437547, BPC 157 for Acute Hamstring Muscle Strain Repair (record dated 27 February 2026, retrieved October 2026). Supports: a planned randomized, double-blind, placebo-controlled phase 2 study; Randomized trial (phase I, healthy volunteers): Wang X et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta 4 in healthy Chinese volunteers. Journal of Cellular and Molecular Medicine, September 2021. PMID 34346165. Supports: NL005 given by vein to healthy volunteers; Animal study (mice): Kannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases, March 2008. PMID 18092346. Supports: anti-inflammatory effects in 2 mouse colitis models; FDA safety page: US FDA web page, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (page dated 22 April 2026, retrieved October 2026). Supports: the GHK-Cu, BPC-157, TB-500 (thymosin beta-4 fragment, LKKTETQ) and KPV entries: immune reaction risk and missing human exposure data; Scoping review: Tewari K et al. Peptide supplements and their therapeutic applications in sports medicine. American Journal of Sports Medicine, 11 August 2026. PMID 42578445. Supports: six peptides reviewed; 67% of papers in animals; human benefit unsubstantiated
GHK-Cu: The Copper Peptide
GHK-Cu has the most human data of the four, and a 2026 systematic review (PMID 42787770) says those human trials are small and mostly on face creams. GHK is a human peptide made of three amino acids: glycine, histidine and lysine. It binds copper to form GHK-Cu.
The human data are limited. A 2026 systematic review says the clinical literature in humans remains thin and fragmented. Most randomized trials are small and were done on facial cosmetic creams. A 2025 review also notes a surprising lack of clinical studies of GHK-Cu in anti-wrinkle products. That is despite wide interest in using it in them.
New work is planned. A study is listed on ClinicalTrials.gov. It will test a GHK-Cu gel on small skin wounds in healthy adults. The question is whether it can safely speed healing. It will be compared with a matching gel without the peptide.
Injected GHK-Cu is a separate question from creams. The FDA says pharmacy-made (compounded) GHK-Cu shots may cause immune reactions. The reasons are that the peptide can clump together and carry impurities. It adds that there are limited human data on safety. See the GHK-Cu profile and the topical GHK-Cu guide for more.
Sources: Review: Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition, 2008. PMID 18644225. Supports: what GHK-Cu is; controlled studies on aged skin (wrinkles, firmness); Systematic review: Najafi N et al. A systematic review of the mechanisms and therapeutic applications of GHK-Cu in topical microneedle delivery. Archives of Internal Medicine Research, July 2026. PMID 42787770. Supports: human trials are small and mostly facial creams; Review: Mortazavi SM et al. Topically applied GHK as an anti-wrinkle peptide: advantages, problems and prospective. BioImpacts, 2025. PMID 39963574. Supports: the absence of clinical studies of GHK-Cu in anti-wrinkle products; Trial registry record: ClinicalTrials.gov record NCT07437586, Topical GHK-Cu Gel for Acute Skin Wound Healing (record dated 27 February 2026, retrieved October 2026). Supports: a planned study of GHK-Cu gel against a vehicle gel; FDA safety page: US FDA web page, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (page dated 22 April 2026, retrieved October 2026). Supports: the GHK-Cu, BPC-157, TB-500 (thymosin beta-4 fragment, LKKTETQ) and KPV entries: immune reaction risk and missing human exposure data
BPC-157: Mostly Animal Studies
BPC-157 rests almost fully on lab and animal work: a 2025 systematic review in HSS Journal (PMID 40756949) included 36 studies, 35 preclinical and 1 clinical. Preclinical means lab and animal studies.
On safety, the same review says preclinical safety studies showed no adverse effects across several organ systems. It also says no clinical safety data were found. In other words, safety in people has not been measured. The review notes BPC-157 lacks US FDA approval and that its use is banned in professional sports.
The FDA says compounded drugs with BPC-157 may pose a risk of immune reactions for some routes. It also points to problems with peptide impurities and with confirming the ingredient itself.
A human trial is now on the registry. ClinicalTrials.gov lists a phase 2 study of BPC-157 after a grade II hamstring strain. It is randomized, double-blind and has a placebo group. The record calls BPC-157 an investigational peptide. Its record describes the plan, not results. More on the BPC-157 profile.
Sources: Systematic review: Vasireddi N et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS Journal, November 2025. PMID 40756949. Supports: 36 studies (35 preclinical, 1 clinical); no clinical safety data; no FDA approval; banned in professional sports; FDA safety page: US FDA web page, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (page dated 22 April 2026, retrieved October 2026). Supports: the GHK-Cu, BPC-157, TB-500 (thymosin beta-4 fragment, LKKTETQ) and KPV entries: immune reaction risk and missing human exposure data; Trial registry record: ClinicalTrials.gov record NCT07437547, BPC 157 for Acute Hamstring Muscle Strain Repair (record dated 27 February 2026, retrieved October 2026). Supports: a planned randomized, double-blind, placebo-controlled phase 2 study
TB-500: No Human Exposure Data
TB-500 has no human data on record, according to the FDA's April 2026 compounding safety page. The FDA lists it as "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500". It says it has not found any human exposure data for drug products with this fragment.
A human trial of a related product does exist, and it is easy to confuse with TB-500. A 2021 phase I trial gave recombinant human thymosin beta 4, called NL005, to healthy volunteers. Recombinant means made by engineered cells. It was given by vein, as single and repeated doses. It looked at safety, how the body handled the drug, and antibodies against it.
That trial drug was recombinant thymosin beta 4, not the short fragment the FDA calls TB-500. Results for one cannot be read across to the other. See the TB-500 profile and TB-500 side effects.
Sources: FDA safety page: US FDA web page, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (page dated 22 April 2026, retrieved October 2026). Supports: the GHK-Cu, BPC-157, TB-500 (thymosin beta-4 fragment, LKKTETQ) and KPV entries: immune reaction risk and missing human exposure data; Randomized trial (phase I, healthy volunteers): Wang X et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta 4 in healthy Chinese volunteers. Journal of Cellular and Molecular Medicine, September 2021. PMID 34346165. Supports: NL005 given by vein to healthy volunteers
KPV: Mouse Data Only
KPV's evidence comes from mice: a 2008 study in Inflammatory Bowel Diseases (PMID 18092346) found anti-inflammatory effects in 2 mouse models of colitis. KPV is a tripeptide derived from a melanocortin, a family of hormones.
The FDA says it has not identified any human exposure data for drug products with KPV, by any route. It also says it lacks important safety information, including whether KPV would cause harm if given to people. More on the KPV profile.
Sources: Animal study (mice): Kannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases, March 2008. PMID 18092346. Supports: anti-inflammatory effects in 2 mouse colitis models; FDA safety page: US FDA web page, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (page dated 22 April 2026, retrieved October 2026). Supports: the GHK-Cu, BPC-157, TB-500 (thymosin beta-4 fragment, LKKTETQ) and KPV entries: immune reaction risk and missing human exposure data
Does KLOW or GLOW Help With Wrinkles?
Neither KLOW nor GLOW has been tested for wrinkles; the skin evidence that exists is for GHK-Cu alone, mostly in creams. A 2008 review (PMID 18644225) reports controlled studies on aged skin.
A 2008 review of GHK points to controlled studies on aged skin. It says they showed GHK-Cu tightens skin and improves elasticity and firmness. It also says it reduces fine lines, wrinkles, sun damage (photodamage) and dark spots (hyperpigmentation). Later reviews are more cautious. The 2026 systematic review calls the human literature thin, with mostly small trials of facial creams. The 2025 review notes a surprising absence of clinical studies in anti-wrinkle products.
So the evidence is about GHK-Cu on the skin, not about a blend taken another way. For skin peptides more broadly, see peptide serums and peptides for skin tightening.
Sources: Review: Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition, 2008. PMID 18644225. Supports: what GHK-Cu is; controlled studies on aged skin (wrinkles, firmness); Systematic review: Najafi N et al. A systematic review of the mechanisms and therapeutic applications of GHK-Cu in topical microneedle delivery. Archives of Internal Medicine Research, July 2026. PMID 42787770. Supports: human trials are small and mostly facial creams; Review: Mortazavi SM et al. Topically applied GHK as an anti-wrinkle peptide: advantages, problems and prospective. BioImpacts, 2025. PMID 39963574. Supports: the absence of clinical studies of GHK-Cu in anti-wrinkle products
How Long Does KLOW Take to Work?
No study gives a time frame for KLOW to work, because we found no study that has tested the blend. Any timeline quoted for it comes from outside the research.
The same is true for the single peptides when injected. BPC-157 has 1 clinical study in the 2025 review and no clinical safety data. TB-500 and KPV have no human exposure data, per the FDA. Without human studies, there is no measured time to effect to report.
None of these four peptides is an FDA-approved medicine. This page describes what studies and the FDA report. It does not tell anyone what to take.
Sources: Systematic review: Vasireddi N et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS Journal, November 2025. PMID 40756949. Supports: 36 studies (35 preclinical, 1 clinical); no clinical safety data; no FDA approval; banned in professional sports; FDA safety page: US FDA web page, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (page dated 22 April 2026, retrieved October 2026). Supports: the GHK-Cu, BPC-157, TB-500 (thymosin beta-4 fragment, LKKTETQ) and KPV entries: immune reaction risk and missing human exposure data
Common Questions
What is the difference between KLOW and GLOW?+
No official source defines either name. So no label or study can confirm the difference. They are seller names, and the mix can vary by seller. Say one label lists KPV and the other does not. The FDA says it has found no human exposure data for KPV by any route.
Which peptide is the most effective?+
No study ranks these peptides against each other. A 2026 review looked at six peptides, including BPC-157, TB-500 and GHK-Cu. It found that 67% of the papers used animals. It said human trials do not yet back up the claimed benefits for recovery and performance.
Does klow peptide help with wrinkles?+
No study has tested KLOW for wrinkles. Of the peptides discussed with it, GHK-Cu has the skin data. A 2008 review says controlled studies on aged skin showed it reduces fine lines and wrinkles. A 2025 review adds that clinical studies of GHK-Cu in anti-wrinkle products are surprisingly absent.
Is GHK-Cu better than Glow peptide?+
No head to head study exists, and no study of a GLOW blend was found. GHK-Cu on its own has small human trials, mostly of facial creams. There is no blend data to compare against.
How long does it take Klow to work?+
There is no answer from research. No human study of KLOW exists, so there is no measured timeline. Any time frame quoted for the blend does not come from a trial.
Which KLOW peptide is the best?+
No source ranks KLOW products. What can be compared is the evidence for each ingredient. GHK-Cu has small human cream trials. BPC-157 has 1 clinical study in a 2025 review. The FDA found no human exposure data for TB-500 or KPV.
Does the glow peptide work?+
It has not been tested as a blend. No study of GLOW or of these peptides combined was found. The individual peptides have mostly lab and animal data, with small human cream trials for GHK-Cu.
Sources: FDA safety page: US FDA web page, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (page dated 22 April 2026, retrieved October 2026). Supports: the GHK-Cu, BPC-157, TB-500 (thymosin beta-4 fragment, LKKTETQ) and KPV entries: immune reaction risk and missing human exposure data; Scoping review: Tewari K et al. Peptide supplements and their therapeutic applications in sports medicine. American Journal of Sports Medicine, 11 August 2026. PMID 42578445. Supports: six peptides reviewed; 67% of papers in animals; human benefit unsubstantiated; Review: Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition, 2008. PMID 18644225. Supports: what GHK-Cu is; controlled studies on aged skin (wrinkles, firmness); Review: Mortazavi SM et al. Topically applied GHK as an anti-wrinkle peptide: advantages, problems and prospective. BioImpacts, 2025. PMID 39963574. Supports: the absence of clinical studies of GHK-Cu in anti-wrinkle products; Systematic review: Najafi N et al. A systematic review of the mechanisms and therapeutic applications of GHK-Cu in topical microneedle delivery. Archives of Internal Medicine Research, July 2026. PMID 42787770. Supports: human trials are small and mostly facial creams; Systematic review: Vasireddi N et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS Journal, November 2025. PMID 40756949. Supports: 36 studies (35 preclinical, 1 clinical); no clinical safety data; no FDA approval; banned in professional sports
Related reading
This guide is for educational purposes only and is not medical advice. It describes what published studies, trial registries and the FDA report about GHK-Cu, BPC-157, TB-500 and KPV. It is not an endorsement or an instruction to use any compound. None of these peptides is approved by the FDA as a medicine. Talk to a qualified healthcare professional before making any decision about your health.